CD47 expression in classic follicular lymphoma is associated with event-free survival

IF 2.7 2区医学 Q2 PATHOLOGY

Human pathology Pub Date : 2025-04-01 DOI:10.1016/j.humpath.2025.105792

Ayako Kume , Sheren Younes , Olivia Colace , Iman Hussain , Etienne Mahe , Rong Lu , Ranjana H. Advani , Adnan Mansoor , Yasodha Natkunam

{"title":"CD47 expression in classic follicular lymphoma is associated with event-free survival","authors":"Ayako Kume , Sheren Younes , Olivia Colace , Iman Hussain , Etienne Mahe , Rong Lu , Ranjana H. Advani , Adnan Mansoor , Yasodha Natkunam","doi":"10.1016/j.humpath.2025.105792","DOIUrl":null,"url":null,"abstract":"<div><div>CD47 inhibits host cell phagocytosis by macrophages, leading to immune evasion. Upregulation of CD47 in many cancers including hematopoietic neoplasms correlates with poor prognosis. We evaluated CD47 expression in classic follicular lymphoma (FL) to ascertain its potential utility for targeted therapy. A cohort of 97 cases were studied by immunohistochemistry using a rabbit anti-CD47 monoclonal antibody and the results were correlated with clinicopathologic features, gene expression and clinical outcome. Our findings show that high CD47 expression (H-score ≥150) was significantly associated with a worse event-free survival at 12 months EFS12 and EFS24 months (<em>P</em> = 0.023 and 0.009 respectively), although no correlation was seen with overall survival (OS; <em>P</em> = 0.175) or other clinicopathologic parameters. In multivariate analysis, H-score retained its impact on both EFS12 and EFS24 (<em>P</em> = 0.027 and 0.0.012, respectively). Gene expression profiling revealed 11 genes that showed statistically significant differences in CD47-high versus CD47-low expressors in univariate but not in multivariate analysis and included <em>MAPK12</em> and <em>CCND2</em>. Validation in larger case cohorts is required to further support the potential application of CD47-targeted approaches in patients with FL and to explore novel therapeutic strategies. In addition, differentially expressed genes in CD47-high versus CD47-low expressors raises potential areas of interest for further study.</div></div>","PeriodicalId":13062,"journal":{"name":"Human pathology","volume":"158 ","pages":"Article 105792"},"PeriodicalIF":2.7000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Human pathology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0046817725000796","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PATHOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

CD47 inhibits host cell phagocytosis by macrophages, leading to immune evasion. Upregulation of CD47 in many cancers including hematopoietic neoplasms correlates with poor prognosis. We evaluated CD47 expression in classic follicular lymphoma (FL) to ascertain its potential utility for targeted therapy. A cohort of 97 cases were studied by immunohistochemistry using a rabbit anti-CD47 monoclonal antibody and the results were correlated with clinicopathologic features, gene expression and clinical outcome. Our findings show that high CD47 expression (H-score ≥150) was significantly associated with a worse event-free survival at 12 months EFS12 and EFS24 months (P = 0.023 and 0.009 respectively), although no correlation was seen with overall survival (OS; P = 0.175) or other clinicopathologic parameters. In multivariate analysis, H-score retained its impact on both EFS12 and EFS24 (P = 0.027 and 0.0.012, respectively). Gene expression profiling revealed 11 genes that showed statistically significant differences in CD47-high versus CD47-low expressors in univariate but not in multivariate analysis and included MAPK12 and CCND2. Validation in larger case cohorts is required to further support the potential application of CD47-targeted approaches in patients with FL and to explore novel therapeutic strategies. In addition, differentially expressed genes in CD47-high versus CD47-low expressors raises potential areas of interest for further study.

查看原文本刊更多论文

CD47在典型滤泡性淋巴瘤中的表达与无事件生存率相关

CD47抑制宿主细胞被巨噬细胞吞噬，导致免疫逃逸。在包括造血肿瘤在内的许多癌症中，CD47的上调与不良预后相关。我们评估了CD47在典型滤泡性淋巴瘤（FL）中的表达，以确定其在靶向治疗中的潜在效用。采用兔抗cd47单克隆抗体对97例患者进行免疫组化研究，研究结果与临床病理特征、基因表达及临床转归的相关性。我们的研究结果显示，高CD47表达（h评分≥150）与EFS12和EFS24个月时较差的无事件生存期显著相关（P分别= 0.023和0.009），尽管与总生存期无相关性(OS；P = 0.175)或其他临床病理参数。在多变量分析中，h分数对EFS12和EFS24均有影响（P分别为0.027和0.0.012）。基因表达谱显示，在单因素分析中，11个基因在cd47高表达与cd47低表达方面存在统计学差异，但在多因素分析中没有统计学差异，其中包括MAPK12和CCND2。需要在更大的病例队列中进行验证，以进一步支持cd47靶向方法在FL患者中的潜在应用，并探索新的治疗策略。此外，cd47 -高表达基因与cd47 -低表达基因的差异表达提出了进一步研究的潜在兴趣领域。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Human pathology 医学-病理学

CiteScore

5.30

自引率

6.10%

发文量

206

审稿时长

21 days

期刊介绍： Human Pathology is designed to bring information of clinicopathologic significance to human disease to the laboratory and clinical physician. It presents information drawn from morphologic and clinical laboratory studies with direct relevance to the understanding of human diseases. Papers published concern morphologic and clinicopathologic observations, reviews of diseases, analyses of problems in pathology, significant collections of case material and advances in concepts or techniques of value in the analysis and diagnosis of disease. Theoretical and experimental pathology and molecular biology pertinent to human disease are included. This critical journal is well illustrated with exceptional reproductions of photomicrographs and microscopic anatomy.